Controlled antipsychotic discontinuation in institutionalized people with intellectual disability

Phase 4, randomised, open-label trial in intellectual disability (ID) (2 arms), sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoint: Proportion developing marked behavioral symptoms requiring antipsychotic prescription escalation and study withdrawal. Started Jul 2019; status: active, not recruiting.